ProCE Banner Activity

Responder a las preguntas clave en el tratamiento óptimo de los pacientes con leucemia linfocítica crónica recidivante/refractaria

Clinical Thought

En esta actividad, los expertos abordan cuestiones clave en el cuidado de los pacientes con leucemia linfocítica crónica (LLC) recidivante/refractaria (R/R), tal y como se debatió durante un seminario web en directo. Estas respuestas proporcionan información práctica y que los médicos que se encuentran muy ocupados pueden utilizar en la clínica. 

Released: December 20, 2024

Expiration: December 19, 2025

Share

Faculty

Othman Al-Sawaf

Othman Al-Sawaf, MD

Department of Hematology and Oncology
University Hospital of Cologne
Cologne, Germany

Farrukh T. Awan

Farrukh T. Awan, MD, MS, MBA

Associate Director, Section of Hematologic Malignancies/Transplantation and Cellular Therapy
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

Alessandra Tedeschi

Alessandra Tedeschi, MD

Medical Doctor
Department of Hematology
Niguarda Cancer Center Milano
Milano, Italy

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Disclosure

Primary Author

Othman Al-Sawaf, MD

Department of Hematology and Oncology
University Hospital of Cologne
Cologne, Germany

Othman Al-Sawaf, MD: consultant/advisor/speaker: AbbVie, Adaptive, AstraZeneca, BeiGene, Gilead, Janssen, Lilly, Roche; researcher: AbbVie, BeiGene, Janssen, Roche.

Farrukh T. Awan, MD, MS, MBA

Associate Director, Section of Hematologic Malignancies/Transplantation and Cellular Therapy
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

Farrukh T. Awan, MD, MS, MBA: consultant/advisor/speaker: AbbVie, Adaptive Biotechnologies, ADCT Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Caribou Biosciences, Dava Oncology, Genmab, Incyte, Kite, Loxo Oncology; researcher: AbbVie/Pharmacyclics.

Alessandra Tedeschi, MD

Medical Doctor
Department of Hematology
Niguarda Cancer Center Milano
Milano, Italy

Alessandra Tedeschi, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeiGene, Johnson & Johnson.